VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
RAPP
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
RAPPRapport Therapeutics, Inc. Common Stock
$23.40$1.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
RAPP logo

Rapport Therapeutics, Inc. Common Stock

RAPP
NASDAQ · Neuroscience Biotech
$23.40
At close - Nov 18, 4:00 PM EST - USD
Market Cap$1.12B
P/E-7.4x
52W High$52.93
Volume696.34K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Pivotal-Stage Burn Outpaces Thin Cash Runway

Rapport Therapeutics has generated essentially no product revenue apart from a single non-recurring $20.0M quarter in 2026Q1, leaving its fundamentals driven entirely by clinical spending, with R&D rising from $15.5M in 2024Q3 to $51.4M in 2026Q2 and quarterly net losses reaching $40.2M to $56.6M.

GrowthMixed
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

RAPP price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

7/12 Beats

EPS beat 7 of last 12 quarters

02

Valuation risk

-118% Peers

P/E is 118% below peer median

03

Market leadership

RS 26 · Lag

Laggard (Underperforming 74% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 4

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
RAPP-16.76%
S&P 500 (^GSPC)+6.88%
1-Year Return
RAPP-7.58%
S&P 500 (^GSPC)+10.62%
3-Year Return
RAPP+12.50%
S&P 500 (^GSPC)+58.57%
5-Year Return
RAPP+12.50%
S&P 500 (^GSPC)+53.24%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E
-7.4x
Forward P/E
N/A
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-7.4x
N/A
N/A
EV/EBITDA
N/A
N/A
N/A
Price/FCF
N/A
N/A
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$1.91-91.8%
Base (Fair)$49.57+89.6%
Bull$1.91-91.8%
$1.91 Bear$49.57 Base$1.91 Bull
Current Market Price: $23.40
Trades at a 52.8% discount to Base DCF ($49.57)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$111M-42.4% YoY
Free cash flow FY25
-$88M-31.0% YoY
Operating margin FY25
-
ROIC (FY25)-27.1%
Avg ROIC 5Y-53.3%
ROE (TTM)-34%
Piotroski Score2 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate7/12 (70%)
Revenue Beat Rate1/12 (100%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 4, 2026
-$0.84+28.8%
vs -$1.18
—
vs $7,690
Q3 2026
Aug 5, 2026
-$1.19-23.6%
vs -$0.96
—
vs $2M
Q2 2026
May 7, 2026
-$0.42+25.0%
vs -$0.56
$20M+166.7%
vs $8M
Q2 2026
Mar 10, 2026
-$0.72-10.8%
vs -$0.65
—
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·Nov 4, 2026
Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update

Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027 Data from the Phase 2 FOS open-label long-term safety trial expected in 4Q 2026; Phase 3 FOS trials enrolling patients Well-capitalized with $815.4 million1 in cash and cash equivalents as of November 3, 2026, and runway through the end of 2029 BOSTON and SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a business update, including a summary of the recently announced positive topline results from its Phase 2 trial of RAP-219 in adults with acute bipolar mania and updates across the RAP-219 development program and pipeline. “We continue to deliver on our priorities with strong execution across the portfolio,” said Abraham N.

GlobeNewsWire·Nov 3, 2026
Rapport Therapeutics to Participate in Upcoming Investor Conferences

BOSTON and SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced that management will participate in two upcoming investor conferences. Stifel 2026 Healthcare Conference (New York City, NY) Fireside chat on Wednesday, November 11, 2026, at 1:20 – 1:50 p.m.

GlobeNewsWire·Nov 2, 2026
Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement

BOSTON and SAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced the closing of its previously announced separate underwritten public offerings of 9,761,905 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase up to 1,428,571 additional shares of its common stock, at a public offering price of $21.00 per share (the “Offering Price”) and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to 1,190,476 shares of its common stock at an offering price of $20.999 per pre-funded warrant, which represents the per share Offering Price less the $0.001 per share exercise price for each pre-funded warrant (the “common stock offering”) and $172.5 million aggregate principal amount of 2.25% convertible senior notes due 2032 (the “notes”), which includes the exercise in full of the underwriters' over-allotment option to purchase up to an additional $22.5 million aggregate principal amount of notes (the “notes offering” and together with the common stock offering, the “underwritten offerings”). Concurrently with the underwritten offerings, Rapport entered into a securities purchase agreement with a certain investor (the “Investor”), in a separately negotiated transaction (the “concurrent private placement” and together with the underwritten offerings, the “offerings”) pursuant to which Rapport sold to the Investor 1,428,571 shares of Rapport's common stock, at the Offering Price.

GlobeNewsWire·Oct 28, 2026
Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement

BOSTON and SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced the pricing of separate underwritten public offerings of approximately $175.0 million of shares of its common stock at an offering price of $21.00 per share (the “Offering Price”) and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to approximately $25.0 million of shares of its common stock at an offering price of $20.999 per pre-funded warrant, which represents the per share Offering Price less the $0.001 per share exercise price for each pre-funded warrant (the “common stock offering”) and $150.0 million aggregate principal amount of 2.25% convertible senior notes due 2032 (the “notes”) (the “notes offering” and together with the common stock offering, the “underwritten offerings”). Concurrently with the underwritten offerings, Rapport entered into a share purchase agreement with a certain investor (the “Investor”), in a separately negotiated transaction (the “concurrent private placement” and together with the underwritten offerings, the “offerings”) pursuant to which Rapport agreed to offer and sell, and the Investor agreed to purchase, approximately $30.0 million of shares of Rapport's common stock, at the Offering Price. The sale of shares to the Investor in the concurrent private placement will not be registered as part of the common stock offering.

Filtered for Rapport Therapeutics, Inc. Common StockMore Headlines
04

Compare before deciding

Benchmark RAPP against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Rapport Therapeutics, Inc. Common Stock (RAPP)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
RAPP logoRAPPRapport Therapeutics, Inc. Common StockCurrent
$23.40$1.12B-7.43—-752.35%-34%—
PTCT logoPTCTPTC Therapeutics, Inc.
$60.23$5B-47.44114.51%-9.17%——
ACAD logoACADACADIA Pharmaceuticals Inc.
$17.83$3.05B8.6411.87%30.13%28.03%—
PRAX logoPRAXPraxis Precision Medicines, Inc.
$305.19$8.51B-24.78-100%—-29.41%—
INVA logoINVAInnoviva, Inc.
$18.40$1.36B6.8618.52%43.79%15.84%—
NKTR logoNKTRNektar Therapeutics
$34.42$1.18B-6.64-43.89%-339.67%-29.31%—

Compare RAPP vs Peers

Rapport Therapeutics, Inc. Common Stock (RAPP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs PTCT

Most directly comparable listed peer for RAPP.

Scale Benchmark

vs LLY

Larger-name benchmark to compare RAPP against a more recognizable public peer.

Peer Set

Compare Top 5

vs PTCT, ACAD, PRAX, INVA

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

RAPP SEC Filings & Documents

Rapport Therapeutics, Inc. Common Stock (RAPP) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 4, 2026·SEC

Material company update

Oct 30, 2026·SEC

Material company update

Oct 20, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 10, 2026·SEC

FY 2025

Mar 11, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 4, 2026·SEC

FY 2026

Aug 5, 2026·SEC

FY 2026

May 7, 2026·SEC

Get notified when RAPP posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

RAPP Frequently Asked Questions

Rapport Therapeutics, Inc. Common Stock (RAPP) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Rapport Therapeutics, Inc. Common Stock's revenue?

Rapport Therapeutics, Inc. Common Stock (RAPP) reported $20.0M in revenue over the trailing twelve months.

Is RAPP profitable?

No. Rapport Therapeutics, Inc. Common Stock (RAPP) reported a net loss of $150.5M over the trailing twelve months.

Dividend & Returns
What is RAPP's return on equity?

Rapport Therapeutics, Inc. Common Stock (RAPP) had a return on equity (ROE) of -34.0% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Rapport Therapeutics, Inc. Common Stock's free cash flow?

Rapport Therapeutics, Inc. Common Stock (RAPP) had negative free cash flow of $121.2M over the trailing twelve months.

What if you invested $1,000 in RAPP back in 2022?

Total return calculator · dividends reinvested · 4+ years of data

See returns →